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Two human hepatitis viruses have been identified and characterized, but one or more
additional agents exist. Hepatitis B virus (HBV) is a complex 42-nm predominantly double-
stranded DNA virus with distinct surface and core antigens and an endogenous DNA
polymerase. Hepatitis A virus (HAV) is a 27-nm RNA virus with enterovirus-like properties.
Progressively more sensitive and specific immunologic assays have been applied to the study of
viral hepatitis and are available for routine diagnostic purposes. As a result we recognize
distinct serologic response patterns to infection, new antigenic markers, biochemical-
biophysical characteristics of the viruses, and their epidemiologic features. Recombinant DNA
technology has permitted the cloning of HBV genetic material and gene products in E. coli, but
the virus has not been cultivated in vitro. In contrast, successful in vitro cultivation of HAV has
finally been accomplished. Application of sensitive serologic tests for HAV and HBV has
revealed that "non-A, non-B" agents account for a substantial proportion of transfusion-
associated hepatitis as well as hepatitis occurring in the absence of percutaneous exposure.
These agents have been transmitted to chimpanzees, and several putative virus antigen-antibody
systems have been described; however, a specific association between these virus antigens and
non-A, non-B hepatitis has not been established.
INTRODUCTION
Traditional classification of viral hepatitis was based on epidemiologic observa-
tions and studies in volunteers which suggested the existence of two types of
infection. One had a short incubation period (two to six weeks), was spread by the
fecal-oral route, occurred in large common-source outbreaks, and, considered highly
infectious, was designated "infectious hepatitis." The other, labelled "serum hepati-
tis," was associated with percutaneous inoculation of blood or instruments contami-
nated with blood, had a long incubation period (six weeks to six months), and was
not spread as readily from person to person. The discovery of virus antigens and
animal models and the development of serological tests for the agents of viral
hepatitis, however, have changed radically our traditional concepts and continue to
broaden our understanding of the viruses which cause hepatitis in man.
VIRAL HEPATITIS, TYPE B
Australia antigen, discovered in the early 1960s, is known today to represent an
antigenic specificity, hepatitis B surface antigen (HBsAg), on the surface of three
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morphologically distinct forms: spherical particles approximately 22 nm in diameter,
tubules of similar diameter but ofvarying length, and the 7-nm outer coat of a 42-nm
double-shelled structure, the hepatitis B virion (Dane particle). The 22-nm spheres
and tubules are thought to represent excess viral coat protein and circulate in
sufficient abundance to be detected byrelatively insensitive immunologic techniques.
In infected liver cells, HBsAg activity is localized to the cytoplasm where it can be
demonstrated in chronically infected persons by immunofluorescence or immunoper-
oxidase staining techniques; by the presence in paraffin sections of "ground-glass"
hepatocytes, orcein or aldehyde-fuchsin staining; or by electron microscopy. Hepati-
tis B surface antigen consists ofapproximately seven polypeptides as well as lipid and
carbohydrate components. Residing on each HBsAg particle is a group-reactive
determinant,a, and, generally, mutually exclusive allelic subdeterminants d, y and w,
r as well as a number of other recently described but less well-characterized
subdeterminants. As a result, four virus genome-determined major subtypes of
HBsAg were recognized: adw, ayw, adr, and ayr, but the recent recognition of w
variantsw,, W2, W3, and W4 as well as other specificities has expanded this group of
major subtypes. Different subtypes are characteristic of different geographic locales
and tend to distinguish certain special epidemiologic settings, but, with the exception
of an association between ayw strains and infantile papular acrodermatitis, the virus-
coded subtype does not correlate with severity, outcome, or extrahepatic syndromes
of hepatitis B virus (HBV) infection.
Within the hepatitis B virion and exposed by detergent or lipid solvent treatment is
a 27-nm nucleocapsid core, called hepatitis B core antigen (HBcAg), immunologi-
cally unrelated to HBsAg and to which the host mounts a distinct immune response.
In chronically infected persons, HBcAg is localized by immunologic techniques
primarily, but not exclusively, to the hepatocyte nucleus, where 27-nm particles can
be visualized by electron microscopy. Hepatitis B core antigen consists of two,
perhaps three, polypeptides and there is no subtype heterogeneity to this antigen.
Within the core is a circular DNA genome with a molecular weight of approximately
2 x 106 daltons of which 70 percent is double-stranded and the remainder single-
stranded [1,2]. This genome with double- and single-stranded segments is unique to
HBV and to the virusof a- recently discovered agent in woodchucks, woodchuck
hepatitis virus, which is morphologically similar to HBV and is associated with acute
and chronic hepatitis and hepatocellular carcinoma in this species [3]. Also within the
core is a HBV-specific DNA-dependent DNA polymerase which uses HBV DNA as a
primer template and which has the potential in vitro to make double-stranded the
single-stranded region of the genome [1]. The recent application of recombinant
DNA technology has accelerated characterization and allowed more accurate
restriction endonuclease mapping of the HBV genome [4,5]. Furthermore, the
elaboration of HBcAg by E. coli which had incorporated parts of the HBV genome
has been described [4]. Thus, despite refractoriness of HBV to cultivation in tissue
culture, elaboration of viral gene products can be studied in vitro. In the same vein,
establishment of a HBsAg-secreting cell line, PLC/ PRF/5, derived from a patient
with hepatic cell carcinoma and HBV infection [6], provides another in vitro model
of virus gene product synthesis.
Twosubpopulations ofhepatitis B virions (Dane particles) have been described [7].
One appears "full" when examined by electron microscopy, has a buoyant density in
cesium chloride(CsCl) of 1.22 g/cm3, and contains DNA and DNA polymerase. The
other appears "empty," has a lighter density of 1.20 g/cm3, is devoid of or has an
incomplete genome and lacks DNA polymerase. The existence of these incomplete
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virions is reminiscent of defective interfering particles described in association with
such agents as vesicular stomatitis virus and lymphocytic choriomeningitis virus.
These defective particles could compete with complete virions for hepatocyte
receptor sites or require cooperation from a complete virion for replication. In well-
defined systems of defective interference, these incomplete particles appear to
facilitate establishment of a non-cytopathic persistent infection tolerated by the host.
It is attractive to speculate that similar interference by lighter virions contributes to
the modulation of HBV infection which eventuates in a chronic carrier state.
During the course of HBV infection, a well-defined sequence of serological events
occurs. The earliest detectable finding, occurring several weeks after exposure, is
HBsAg in serum. Shortly after HBsantigenemia begins, antibody to the core of HBV
(anti-HBc) becomes detectable in high titer, long before appreciable levels of anti-
HBs can be detected and roughly coincident with the transient appearance of DNA
polymerase activity, days to weeks before or coincident with elevation of serum
aminotransferase activity. (Hepatitis B core antigen circulates within the intact
virion; therefore, it is immunologically sequestered and not detectable in the
circulation.) In self-limited acute cases, HBsAg levels diminish gradually, anti-HBc
titers fall, and appreciable levels ofantibody to HBsAg(anti-HBs) become detectable
several weeks to months after the disappearance of HBsAg. Both anti-HBs and anti-
HBc remain detectable for years after infection but at relatively lo'w titers. In
approximately 10 percent of cases, HBsAg never reaches detectable levels (<109
particles/ ml); in such instances a diagnosis of HBV infection is made by demonstra-
tion of an anti-HBc/anti-HBs response. In fact, anti-HBc may be the only indicator
of HBV infection during the interval or "window" between disappearance of HBsAg
and emergence of anti-HBs [8]. Moreover, the fact that HBsAg-negative, anti-HBs-
negative blood containing anti-HBc has been implicated in the transmission oftype B
hepatitis to transfusion recipients [9] and the demonstration that anti-HBc-positive
blood may contain HBsAg at levels beneath the sensitivity threshold of radioimmu-
noassay suggest that high titeranti-HBc is a sensitive indicator ofongoing hepatitis B
viral replication even in the absence of detectable circulating HBsAg.
The most important variation on the theme of standard serologic events is the
chronic HBsAg carrier state. In carriers, HBsAg remains detectable in the circulation
indefinitely, anti-HBc increases in titer, but anti-HBs is generally not detectable with
currently available assays. These observations and deductions derived from sero-
epidemiologic investigations suggest that anti-HBc is not protective but reflects recent
or current viral infection, especially when present in high titer. In contrast, anti-HBs
appears to be the protective antibody, and its presence in the circulation is the goal of
strategies for passive and active immunization. Currently, trials are under way to
evaluate a HBV vaccine prepared from plasma ofchronic carriers by purifying 20-nm
HBsAg particles to render them free of complete virions by ultracentrifugation
[10,11].
A less well-characterized antigen associated with HBV infection, but one which has
been the recent object of intense study, is hepatitis B e antigen (HBeAg) [12]. This
antigen, or group ofantigens (el, e2, and e3 have been identified), is a soluble protein
found in HBsAg-positive serum and correlates with the presence of intact virions,
DNA-polymerase activity, and HBsAg in high titer, i.e., with ongoing viral synthesis.
As such, HBeAg identifies HBsAg-positive persons whose infectivity is likely to be
high[13,14]. Individuals with HBV infection who are anti-HBe-positive are much less
likely to be infectious. No longer believed to correlate well with severity or chronicity
of liver disease, HBeAg appears early, transiently during acute type B hepatitis [15].
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Although its biological significance is not fully appreciated, HBeAg, which is
immunologically distinct from HBsAg and HBcAg, appears to be associated with
and to share polypeptides of HBcAg [16]. Preliminary reports localize HBeAg to the
nucleus of infected hepatocytes.
Recently, a number of new antigenic markers have been associated with HBV
infection, including "delta" antigen [17] and an antigen unique to the surface of the
intact virion [18]; however, these have not been studied extensively. A most
intriguing discovery is that HBsAg particles from some individuals bear receptors for
polymerized human or chimpanzee serum albumin [19]. Concentration and presence
of these receptors correlate with the presence of HBeAg, and, therefore, the presence
of these receptors is an indirect indicator of infectivity. Additional study of these
receptors may elucidate the hepatotropism of HBV and the limitation of its host
range to humans and chimpanzees.
Advances in the study of HBV have evolved from immunologic identification of
virus antigens and antibodies. Once identified in serum with such relatively insensi-
tive methods as agar gel immunodiffusion (AGD), counterelectrophoresis (CEP),
and complement fixation (CF), HBsAg is now detected by one of a variety of
sensitive "third-generation" immunologic methods. Those that have achieved the
greatest reliability and widest use for large-scale, rapid screening are solid-phase
radioimmunoassay (RIA) [20], immune adherence hemagglutination (IAHA) [21],
and enzyme-linked immunosorbent assay (ELISA) [22]. Agar gel diffusion and CEP
are too insensitive to detect anti-HBs in any but the most strongly positive sera.
Instead, passive hemagglutination (PHA) [23] and several modifications of RIA,
including radioimmunoprecipitation [24], are the most sensitive and widely used. In
addition, IAHA and ELISA are being applied to anti-HBs testing. Methods applied
widely to detection of anti-HBc, in ascending order of sensitivity, are CF, CEP,
IAHA, and RIA. For several years, insensitivity of methods to detect HBeAg and
anti-HBe remained an obstacle to the investigation of this antigen-antibody system.
Use of AGD to detect HBeAg or anti-HBe required lengthy incubations and yielded
very faint immunodiffusion lines; results obtained by CEP were obtained more
quickly but without increased sensitivity and even perhaps at the expense of
specificity. Today, techniques of "third-generation" sensitivity, PHA, RIA, and
ELISA, are being applied to the study of this antigen-antibody system. With these
newer techniques, laboratory diagnosis of viral hepatitis type B has been simplified.
A diagnosis of type B hepatitis is based on demonstration of serum HBsAg or de
novo appearance of anti-HBc and anti-HBs. The presence of HBeAg in HBsAg-
positive serum suggests that the serum is likely to be infectious for contacts.
Finally, although a discussion of the epidemiology of HBV [25] is beyond the
present scope, several salient points deserve mention. Parenteral inoculation with
contaminated blood products was once thought to be the only mode of HBV
transmission; however, more recent studies implicate or suggest many non-
percutaneous routes as well. Hepatitis B surface antigen has been found in virtually
every body secretion, some of which are transferred to contacts without introduction
via the percutaneous route. Among such modes of transmission, vertical (from
mother to infant), venereal, and oral spread are probably the most important. Given
the fact that nonpercutaneous routes and other secretions have been implicated in
transmission of HBV, the term "serum" hepatitis is no longer appropriate to describe
hepatitis type B. In fact, serologic testing has shown that approximately one-half of
all sporadic cases lacking percutaneous exposure and once designated as"infectious"
hepatitis are actually caused by HBV [26].
64HEPATITIS VIRUSES
VIRAL HEPATITIS, TYPE A
Studies in volunteers and epidemiologic investigations demonstrated that hepatitis
A virus (HAV) is excreted in feces late in the incubation period and early during the
acute phase of illness; however, attempts to identify the virus in stool were not
successful until Feinstone et al. [27] applied the technique of immune electron
microscopy (IEM) to the study of type A hepatitis. Convalescent serum or immune
serum globulin, known to contain antibody to the virus, was incubated with acute
phase stool specimens from individuals experimentally infected with the MS-1 strain
of HAV. In the immune precipitate that formed, virus-like particles were identified
by electron microscopy; the specificity of the association between these particles and
HAV was proven by serological means and upheld by reports of immunologically
indistinguishable particles in stools of naturally infected persons. Hepatitis A virus
particles were also detected in liver and serum of experimentally infected marmoset
monkeys [28].
Hepatitis A virus is 27 nm in diameter, has a range of buoyant densities in CsCl
from 1.27-1.45 g/cm3 but a principal density of 1.34 g/cm3, and a sedimentation
coefficient of 160S. The non-enveloped virion has cubic symmetry and may appear
"full" (unpenetrated by stain) or "empty" (penetrated by stain). Within the hepato-
cyte, HAV is localized to the cytoplasm, where it has been visualized in vesicular
structures. Its genome is a single-stranded RNA with a molecular weight of 1.9 x 106
daltons, and its four polypeptides are similar in molecular weight to those of
enteroviruses. Like other enteroviruses, HAV is ether- and acid-resistant, but the heat
stability of HAV is uncharacteristic of this group of viruses. In general, however,
HAV most closely resembles the enterovirus subgroup ofpicornaviruses. To date, all
HAV strains described have been immunologically indistinguishable and only one
antigen has been identified with the virion.
Recent advances in hepatitis A research have been fostered by the development of
immunologic assays to detect virus antigen and antibody. Hepatitis A virus has been
purified from stool and liver by ultracentrifugation, electrophoresis, gel filtration,
and affinity chromatography for use as antigen in serological tests. In addition to
IEM, which can be used to detect and quantitate both HAV and anti-HAV, more
simple, practical tests haveemerged, including CF[29], IAHA[30], RIA [31-33], and
ELISA [34,35]. Moreover, HAV can be demonstrated in tissue by immunofluores-
cence [36] and immunoperoxidase [37] staining.
With these techniques investigators have defined the following sequence of
detectable virologic and serologic events during HAV infection in humans and
nonhuman primates: within one to two weeks after exposure, HAV can be detected
by immunofluorescence in the liver where it remains detectable for several weeks,
generally outlasting the brief period of fecal HAV shedding and elevated serum
aminotransferase activity. Viremia is also an early event which, demonstrated by
infectivity of serum, is most pronounced during the late incubation period and
persists no more than a few days after the onset of illness. Generally, the concentra-
tion of HAV in serum is too low for detection by in vitro immunologic techniques.
Shedding of the virus in feces is one of the earliest virologic events detectable with in
vitro techniques in routinely available clinical material. Fecal excretion of HAV
coincides with the onset of non-specific symptoms (malaise, fatigue, anorexia, etc.)
and peaks in intensity several days to more than a week before biochemical and
histologic evidence of acute hepatitis. By the time a patient presents to a physician
with jaundice the bulk of fecal HAV excretion will have already occurred [38].
Serum antibody to HAV appears during the onset ofacute illness, increases in titer
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and readily detectable years after infection. Although anti-HAV can be detected
during acute illness by most of the techniques described above, there is a delay of
from one to four weeks after acute illness before anti-HAV is detectable by IAHA.
Theoretically, then, a combination in acute phase serum of a negative IAHA test for
anti-HAV with anti-HAV detectable by one of the other serologic techniques
provides presumptive evidence for acute HAV infection [39]. Antibody which
appears during early acute illness is predominantlyIgM, which appears transiently.
Antibody of the IgG class develops more gradually, reaches high levels during
convalescence, and persists for years, if not indefinitely. Anti-HAV is protective; its
presence in serum indicates previous HAV infection and immunity to reinfection.
For practical purposes, clinical laboratory diagnosis usually depends on demon-
stration of a serologic response in paired acute and convalescent serum samples or of
anti-HAV of theIgM class [40,41] during acute illness.
Eluding investigators for several decades, successful cultivation of HAV in vitro
has finally been accomplished. Provost and Hilleman [42] recently reported serial
propagation of the CR326 strain of HAV, which had been passaged extensively in
marmosets, in primary explant cultures of adult Saguinus labiatus marmoset livers
and, even more efficiently, in a fetal rhesus monkey kidney cell line (FRhK6). Unlike
other enteroviruses which are cytopathic in cell culture, HAV was not cytopathic in
these cell lines; its presence was monitored by immunofluorescence. Although direct
inoculation of clinical specimens from man into tissue culture is not yet feasible as a
diagnostic tool, this work does represent an important breakthrough for hepatitis A
research and for hepatitis research in general.
Seroepidemiologic studies have shown that exposure to HAV is widely distributed
and increases as a function ofincreasing age and decreasing socioeconomic class. In
modern urban societies, a decrease in the incidence of HAV infection has occurred,
and age-related differences in prevalences of HAV exposure reflect this change. Type
A hepatitis is transmitted almost exclusively by fecal-oral spread, which is enhanced
by poor personal and environmental hygiene. There is no virologic, epidemiologic, or
clinical evidence for the existence of viremic or intestinal HAV carriers, and the virus
is rarely, ifever, spread in nature byparenteral mechanisms. Perpetuation of HAV in
nature appears to depend on non-epidemic, inapparent infection [43,44].
NON-A, NON-B VIRAL HEPATITIS
Once sensitive serologic tests for both HBV and HAV infection became available,
their application revealed that, today, 80-90 percent of cases of transfusion-
associated hepatitis are not caused by either of these recognized human hepatitis
viruses [45,46]. These cases, designated "non-A, non-B" hepatitis, are also unrelated
to other known viruses which occasionally affect the liver and occur in a variety of
non-transfusion epidemiologic settings paralleling those implicated in the trans-
mission of HBV. Chronic hepatitis may be seen in 30-40 percent of patients with
transfusion-associated hepatitis non-A, non-B, and epidemiologic evidence favors the
existence of an asymptomatic chronic carrier state for this agent. Actually, there is
also evidence to suggest the existence of more than one such non-A, non-B agent
[47,48].
The most convincing evidence for the existence of non-A, non-B agents derives
from transmission studies in volunteers and successful serial transmission in
chimpanzees. Although a number of putative non-A, non-B ("hepatitis C") virus
antigen-antibody systems have been defined by such techniques as agar gel diffusion
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[49], electron microscopy [50], and immunofluorescence [51], no viral agent or
immunologic marker has been identified which fulfills accepted serologic criteria for
a specific association with non-A, non-B hepatitis.
IN THE FUTURE
In the years to come, new virologic markers for HBV will be better defined and
studied on a larger scale. Hepatitis B vaccines, some already produced, will be tested
and made available to high-risk populations, and attempts will be made to abort
chronic HBV carriage with antiviral chemotherapy. Improved understanding of the
molecular virology and viral genetics of HBV will derive from studies of woodchuck
hepatitis virus and from recombinant DNA and monoclonal antibody technologies.
Additional work will also be required to pursue the intriguing association between
HBV and hepatocellular carcinoma.
Serologic tests for HAV infection are now commercially available and will be
applied to diagnosis and epidemiologic investigation. The ability to cultivate HAV in
vitro will provide limitless new horizons for its study and should answer questions
remaining about the composition of its genome and its capsid polypeptides.
For non-A, non-B hepatitis, the most pressing task is identification of the agent(s)
and development of simple, sensitive, specific serologic tests. Availability of such
tests is expected to curtail the incidence of transfusion-associated hepatitis and allow
characterization of the elusive agents.
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